TranslatePriority 2 from the Bipolar PSP
| UNCERTAINTY: How can treatments be tailored to individuals? (JLA PSP Priority 2) | |
|---|---|
| Overall ranking | 2 |
| JLA question ID | 0041/2 |
| Explanatory note | Not available for this PSP |
| Evidence | None identified |
| Health Research Classification System category | Mental Health |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | For full examples, see Category ID T12 on spreadsheet. Which new drug treatments are being developed and will they ever be based on a patient's genetic makeup? ~ Cancer treatments seem to be tailored to the type of cells targeted. Are there any plans to produce targeted meds for different types of bipolar? ~ What causes some people to respond to lithium treatment and some not to? ~ How do you determine the right treatment for the patient without experimenting on the patient in a trial and error fashion? ~ Why do medications differ so greatly in effectiveness for what (on the surface) appears to be identical cases? |
| Submitted by | Patients x 41 ~ Carers x 17 ~ Health Professionals x 5 ~ Others x 1 |
| PSP information | |
|---|---|
| PSP unique ID | 0041 |
| PSP name | Bipolar |
| Total number of uncertainties identified by this PSP. | 363 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 14 June 2016 |
